open access
Vol 71, No 2 (2021)
Invited editorial
Published online: 2021-04-06
Get Citation
Well-differentiated neuroendocrine neoplasms (NENs) of the digestive system – a diagnostic and therapeutic problem
1, 2
Affiliations- Department of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
- The Oncological and Reconstructive Surgery Clinic, M. Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
open access
Vol 71, No 2 (2021)
Invited editorial
Published online: 2021-04-06
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Well-differentiated neuroendocrine neoplasms (NENs) of the digestive system – a diagnostic and therapeutic problem
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Invited editorial
Pages
115-116
Published online
2021-04-06
Page views
419
Article views/downloads
405
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2021;71(2):115-116.
Authors
Daria Handkiewicz-Junak
Agnieszka Czarniecka
References (10)- Baldys-Waligorska A, Nowak W. Neuroendocrine neoplasms of the digestive system-current classification and terminology. Nowotwory Journal of Oncology. 2021; 71(1): 26–37.
- Manguso N, Gangi A, Nissen N, et al. Long-Term Outcomes after Elective Emergency Surgery for Small Bowel Neuroendocrine Tumors. Am Surg. 2018; 84(10): 1570–1574.
- Sundin A, Arnold R, Baudin E, et al. Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017; 105(3): 212–244.
- Knigge U, Capdevila J, Bartsch DK, et al. Antibes Consensus Conference Participants, Antibes Consensus Conference participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017; 105(3): 310–319.
- Caplin ME, Pavel M, Ćwikła JB, et al. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(3): 224–233.
- Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124–2130.
- Eriksson J, Garmo H, Hellman P, et al. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol. 2017; 24(5): 1214–1220.
- Yao JC, Fazio N, Singh S, et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016; 387(10022): 968–977.
- Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017; 10(1): 132–141.
- Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376(2): 125–135.